Inclusion Criteria:

          -  Age ≥ 18 (or as required by local regulation).

          -  Histological or cytological confirmation of advanced/metastatic ALK+ NSCLC.

          -  Pretreated with up to three prior lines of an ALK TKI treatment, including at least
             one prior line of a second or third-generation ALK TKI (alectinib, brigatinib,
             ensartinib, or lorlatinib) in Phase 1.

          -  ECOG performance status ≤ 1.

          -  Existence of measurable or evaluable disease (according to Response evaluation
             criteria in solid tumors [RECIST v1.1] criteria).

          -  Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal
             carcinomatosis are eligible.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Major surgery within four weeks of the start of TPX-0131 treatment.

          -  Clinically significant cardiovascular disease

          -  Any of the following cardiac criteria:

               -  Mean resting corrected QT interval (QTc) > 470 msec obtained from three ECGs and
                  any factors that increase the risk of QTc prolongation or arrhythmic events

               -  Any clinically important abnormalities in rhythm, conduction, or morphology of
                  resting ECG

          -  Known clinically significant active infections not controlled with systemic treatment
             (bacterial, fungal, viral including HIV positivity).

          -  Gastrointestinal disease or other malabsorption syndromes that would impact drug
             absorption.

          -  Subjects being treated with or anticipating the need for treatment with strong CYP3A4
             inhibitors or inducers.

          -  Subjects with current or anticipated need for drugs that are sensitive CYP2C9
             substrates with narrow therapeutic indices.